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ABSTRACT
Ewing Sarcoma is a rare bone and soft tissue malignancy affecting children and 
young adults. Chromosomal translocations in this cancer produce fusion oncogenes 
as characteristic molecular signatures of the disease. The most common case is the 
translocation t (11; 22) (q24;q12) which yields the EWS-Fli1 chimeric transcription 
factor. Finding a way to directly target EWS-Fli1 remains a central therapeutic 
approach to eradicate this aggressive cancer. Here we demonstrate that treating 
Ewing Sarcoma cells with JQ1(+), a BET bromodomain inhibitor, represses directly 
EWS-Fli1 transcription as well as its transcriptional program. Moreover, the Chromatin 
Immuno Precipitation experiments demonstrate for the first time that these results are 
a consequence of the depletion of BRD4, one of the BET bromodomains protein from 
the EWS-Fli1 promoter. In vitro, JQ1(+) treatment reduces the cell viability, impairs 
the cell clonogenic and the migratory abilities, and induces a G1-phase blockage as 
well as a time- and a dose-dependent apoptosis. Furthermore, in our in vivo model, 
we observed a tumor burden delay, an inhibition of the global vascularization and 
an increase of the mice overall survival. Taken together, our data indicate that 
inhibiting the BET bromodomains interferes with EWS-FLi1 transcription and could 
be a promising strategy in the Ewing tumors context.
INTRODUCTION
Ewing Sarcoma is the second most common bone 
cancer after Osteosarcoma. It is nonetheless an infrequent 
tumor, mostly affecting children and young adults, with 
a peak of incidence around 15 years [1]. Described for 
the first time in 1921 by James Ewing [2], it mainly 
arises at the pelvic bones, the diaphysis of the lower 
extremities’ long bones and the chest wall’s bones. The 
standard of care for young patients suffering from Ewing 
Sarcoma is based on a multimodal therapy including 
surgical resection associated with local radiotherapy 
and chemotherapy combination [1, 3–5]. This strategy 
has markedly improved the patient outcome worldwide, 
since the 5-year survival rates after treatment are currently 
around 60–70% for the localized forms. Nonetheless, 
these rates dramatically fall around 20–40% in metastatic 
diseases, depending on the metastatic sites and burden [6]. 
The unsatisfactory prognosis of such patients and the fact 
that the toxicity thresholds have already been achieved 
underscore the necessity to find novel therapeutic strategy.
Since 1992, this cancer is well characterized by 
the reciprocal translocation t (11;22) (q24;q12), found in 
85% of these tumors. This translocation leads to the gene 
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fusion between the 5ʹ segment of the EWSR1 gene (Ewing 
sarcoma breakpoint region 1) on the chromosome 22 and 
the 3ʹ portion of Fli1 (Friend leukemia virus integration 
site 1), located on the chromosome 11 [7]. It gives 
birth to the chimeric protein EWS-Fli1, which behaves 
as an aberrant transcription factor at the origin of the 
tumorigenic potential of Ewing Sarcoma cells [8]. EWS-
Fli1 indeed acts as a pivotal transcriptional modulator, up-
regulating target genes such as c-myc [9–11], ID2 [11], 
Cyclin D1 (CCND1) [11, 12], Gli1 [13], MMP-3 [14], 
VEGFA [15, 16], NR0B1 [17, 18], FOXM1 [19] or EZH2 
[20], implicated in cell cycle, invasion and proliferation 
pathways. EWS-Fli1 has also a transcriptional repressor 
role [21], as it is able to directly inhibit the expression of 
some tumor suppressor genes such as p21 [22], p57kip [10], 
TGF-βRII [11, 21, 23] and IGFBP3 [24], often associated 
with development, differentiation and cell communication. 
As Ewing Sarcoma development seems to depend on one 
specific oncogene, targeting its transcription appears as an 
attractive strategy. Moreover, RNA interference studies 
already demonstrated the relevance of this therapeutic 
strategy [25, 26]. Very little is known about the upstream 
epigenetic regulation of EWS-Fli1. A better understanding 
of this fusion-oncogene transcriptional regulation could 
represent an innovative road to improve patient’s clinical 
outcome.
Over the past years, the bromodomain and extra-
terminal domain (BET) proteins have emerged as an 
important class of epigenetic readers. This protein 
subfamily encompasses BRD2, BRD3, BRD4 and BRDT 
and displays gene transcription modulation features by 
its ability to recognize and bind to the N-acetylated-
lysine residues on histone tails [27]. BET bromodomains 
consequently induce an opened-chromatin structure and 
act as scaffold proteins to recruit transcriptional complexes 
and RNA polymerases [28]. The BET proteins are widely 
associated with cancer progression, as it was demonstrated 
that BRD4 has the ability to associate with positive 
transcription elongation factor b (P-TEF-b) to promote the 
G1-S transition of the cell cycle [29]. In addition, the well-
known c-myc oncogene, which is overexpressed in various 
cancers, is directly activated by BRD4 [30, 31]. Therefore, 
several studies report the benefits of targeting the BET 
bromodomains in cancer [32–34]. In Osteosarcoma, BET 
bromodomain inhibition impairs RUNX2 expression 
[31], a pivotal osteoblastic- and tumorigenic-related 
gene [35, 36]. From this perspective, the small cell-
permeable thieno-triazolo-1, 4-diazepine, JQ1, which 
is a potent BET inhibitor, has recently been shown to 
exhibit anti-cancer effects in various cancer models such 
as NMC (NUT midline carcinoma) [37], hematopoietic 
malignancies [38] lung cancer [39], prostate cancer [40] 
and Osteosarcoma [31]. Moreover, strong promoters and 
super-enhancer regulatory regions are frequently found 
to control oncogenes expression [41, 42]. Thus, JQ1 was 
shown to reduce the transcription of such genes, whose 
expression is more sensitive to the BET bromodomains 
presence [41]. Regarding the crucial role of EWS-Fli1 in 
Ewing Sarcoma, we hypothesize that its expression may 
be controlled by such super-enhancers and consequently 
activated by the BET bromodomain activity.
In this study, we explore the role of BET 
bromodomains in the carcinogenesis of Ewing Sarcoma 
in order to evaluate the therapeutic potential of inhibiting 
its epigenetic reading activity both in vitro and in vivo. 
We further uncover that through targeting EWS-Fli1, the 
BET bromodomain inhibitor JQ1 consequently modulates 
the expression level of the downstream EWS-Fli1 network 
genes in Ewing sarcoma cell lines and in in vivo tumor 
models. The JQ1-mediated transcriptional silencing of 
EWS-Fli1 corresponds with the release of BRD4 from 
its loci, which further supports the direct transcriptional 
activation of this gene by BRD4. Taken together and 
considering the EWS-Fli1 oncogene addiction of the 
Ewing Sarcoma cells, our findings indicate that targeting 
the BET bromodomain signaling pathway in Ewing tumor 
can effectively disrupt the progression of this cancer 
through transcriptional repression of its main oncogenic 
driver [43]. In particular, these results provide a novel 
glimpse at the importance of epigenetic mechanisms in 
cancer biology as well as a strong clinical rationale for 
the use of BET bromodomain inhibitors such as JQ1, as a 
potent therapeutic approach for Ewing Sarcoma.
RESULTS
Ewing Sarcoma cell lines are sensitive to BET 
proteins inhibition therapy
To directly assess the relevance of targeting BET 
bromodomain proteins signaling in Ewing Sarcoma 
disease, we first evaluated the messenger RNA expression 
level of BRD2, BRD3 and BRD4 in ten human Ewing 
Sarcoma cell lines. All the cell lines tested expressed 
BRD2, BRD3 and BRD4 at least two times more than 
normal mesenchymal stem cells (MSCs), except the SK-N-
MC cells, potentially because of their neuroblastoma origin 
(Figure 1A). These first data suggest that the majority of 
the Ewing Sarcoma cells express the required molecular 
targets for an efficient BET proteins’ inhibition therapeutic 
strategy. Since the aim of this work is to elucidate the 
potential implication of the BET bromodomains proteins 
on the Ewing Sarcoma’s carcinogenesis through their 
possible regulatory role in EWS-Fli1 expression, the 
EWS-Fli1 mRNA expression level was also assessed 
(Figure 1B). This screening validated the presence of the 
fusion oncogene in all the cell lines tested.
To evaluate the therapeutic potential of BET 
bromodomain inhibition in Ewing Sarcoma, we used 
the JQ1(+) active form of the soluble pharmacological 
inhibitor JQ1, a thienotriazolo-1, 4-diazepine that binds 
selectively to the acetyl-lysine-binding pocket of the BET 
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bromodomain protein (Figure 1C) [44]. The so-called 
JQ1(–), the JQ1 inactive enantiomer does not harbor 
such acetyl-lysine-binding pocket selectivity, and will 
be further used as a negative control. A panel of eleven 
genetically defined human Ewing Sarcoma cell lines was 
treated with the BET inhibitor JQ1(+) to assess its effect 
on cell viability (Figure 1D). A dose-dependent inhibition 
of cell viability was observed in all the cell lines studied 
although with significant variability. The TC32, SKES-1, 
EW7 and RDES cells are the more sensitive ones as 
they exhibited a GI50 between 0.109 and 0.564 µM. With 
GI50 between 1.28 and 2.264 µM, the IOR/BRZ, TC71, 
ASP14, A673-1c, EW24 and SK-N-MC cells display 
an intermediate sensitivity. In contrast, the A673 cell 
line is about 5 times less sensitive compared to the first 
ones, with a GI50 of 4.911 µM (Figure 1D). The JQ1(–) 
inactive enantiomer does not show any effect on the 
cell viability (Supplementary Figure S1), confirming the 
specificity of JQ1(+) towards the BET bromodomains. 
Following investigations were performed with the A673 
and TC71 cell lines because of their differences in terms 
of BET bromodomains levels and JQ1(+) sensitivities 
reflecting the heterogeneity of our Ewing Sarcoma cell 
lines. Moreover, those two cell lines can be used for 
mouse in vivo model and represent two different classical 
anatomical Ewing sarcoma locations. The A673 cells 
come from a female donor of 15 years old presenting a 
tumor localized on muscle whereas the TC71 cells come 
from a 22 years old male patient, displaying a recurrent 
humerus sarcoma.
JQ1 inhibits the clonogenicity, the migratory 
potential and induces both a G1-phase cell 
cycle arrest and the apoptosis of human Ewing 
Sarcoma cell lines
In order to evaluate the functional effects of the 
BET proteins inhibition in vitro, we performed a colony 
formation assay in presence of DMSO alone, JQ1(+) 
or JQ1(–). A 2-days treatment with 4 µM of JQ1(+) 
significantly reduces the clonogenic abilities by 48% in 
TC71 (Figure 2A) and 45% in A673 cells (Supplementary 
Figure S2A) compared to the same amount of DMSO alone 
or the same concentration of JQ1(–). Boyden Chambers 
assays also reveals that inhibiting the BET proteins 
significantly reduces the migratory potential of these cell 
lines (Figure 2B and Supplementary Figure S2B). To 
complete this functional study, we performed a cell cycle 
analysis through the propidium iodide staining method 
after a 2-days JQ1 treatment. A 1 µM JQ1(+) treatment 
blocks the proliferation of the TC71 cells, through a 
marked G1 arrest (Figure 2C), whereas this blockage was 
less important in the A673 ones, a significant G2 phase 
could be observed (Supplementary Figure S2C). Neither 
the DMSO alone, nor JQ1(–) have any effect on the cell 
cycle repartition. The differences obtained between the 
two cell lines could probably be due to the cell-relative 
sensitivity to JQ1(+), the A673 displaying a higher 
GI50 than the TC71. In order to better characterize the 
G1 arrest highlighted, Western blot analysis of the cell-
cycle-related proteins was assessed (Figure 2D). The time-
course experiment performed during 3, 6, 24 or 30 hours 
with 4 µM of JQ1(+) shows that the phosphorylated 
form of the Rb protein (P-Rb), not inhibiting E2F, is 
shortly activated after 3 and 6 hours of JQ1(+) treatment 
and then reduced after 24 hours in the TC71, whereas 
the total Rb protein expression level remains stable for 
TC71. The same results were obtained in the A673 cells 
after 30 hours of JQ1(+) treatment (Supplementary 
Figure S2D). This dephosphorylation of Rb is explained 
by the proteins levels of both the Cyclin E1 (CCNE1) 
and the Cyclin D1 (CCND1) that decrease at 30 hours of 
JQ1(+) treatment, principally in the A673 cells (Figure 2D 
and Supplementary Figure S2D). A decrease in P-RB and 
the expression of these cell-cycle-related proteins was also 
demonstrated in a dose-response experiment in both cell 
lines with first effects observable with as little as 0.4 µM 
(Figure 2D and Supplementary Figure S2D).
Reduction of the cell viability and cell cycle arrest 
are well-known dying-cell features. Thus we finally 
wondered if the BET bromodomain inhibition mediated 
by JQ1(+) could result in a cell death induction. To assess 
the caspases-dependent cell death induced by JQ1(+), 
both the caspase 3/7 activity and the level of cleaved poly 
(ADP-ribose) polymerase (PARP) were evaluated after a 
JQ1 treatment. Consistent with the results of the cell death 
manual counting and the study from Hensel et al., the 
caspase 3/7 activity and the PARP cleavage reveal a time-
dependent induction of apoptosis in the cell lines tested 
(Figure 2E, 2F and Supplementary Figure S2E, S2F) [45]. 
In addition, the same methods also confirm that JQ1(+) 
induces a dose-dependent apoptosis both in the TC71and 
the A673 cell lines (Figure 2G, 2H and Supplementary 
Figure S2G, 2H). On the contrary, neither time- nor dose-
dependent apoptosis is induced by a JQ1(–) treatment 
(Figure 2E, 2G, 2H and Supplementary Figure S2E, S2G, 
S2H, S2K). The BET bromodomains inhibition-induced 
apoptosis was thus confirmed both in A673 and in TC71 to 
be caspase-3/7-dependent. Finally, confirmation of cell 
death induction was obtained when TC71 and A673 cells 
were treated with 4 µM JQ1(+) or JQ1(–) during 3, 6, 
24, 30 or 48 hours and a time-dependent induction of 
cell death could be observed when the number of dead 
cells was evaluated by manual counting after Trypan blue 
exclusion (Supplementary Figure S2I, S2J).
Direct transcriptional regulation of EWS-Fli1 by 
BET proteins
EWS-Fli1 expression is considered as the molecular 
signature of the Ewing Sarcoma cells and it is now well 
established that inhibiting this chimeric factor source 
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of oncogene addiction impacts the aggressiveness and 
the cancerous features of these cells [46]. In order to 
determine if EWS-Fli1 could be the mediator at the origin 
of the functional effect of JQ1, we accordingly examined 
its expression after treatment. In all the Ewing Sarcoma 
cell lines tested, JQ1(+) treatment decreased the EWS-
Fli1 mRNA expression in a dose-dependent manner 
(Figure 3A). Indeed, after twenty-four hours of 10 µM 
JQ1(+), the mRNA expression was decreased by 57.1% 
in the A673 cell line and by 39.9% with 4 µM JQ1(+) 
in the TC71 cell line. The different JQ1(+) treatment 
concentrations were picked according to the respective cell 
lines GI50 (Figure 1D). The EWS-Fli1 protein expression 
level was also assessed by Western blotting in these cell 
lines (Figure 3B) and confirms the RT-qPCR results. 
Moreover, as illustrated by the relative quantification of 
the blots, a 0.4 µM JQ1(+) treatment during twenty-four 
hours reduces by 56.4% the TC71-EWS-Fli1 protein 
expression whereas a 4 µM JQ1(+) concentration is 
necessary to obtain the same effect in the A673 cells 
(Supplementary Figure S3). These results finally support 
the fact that the TC71 cell line is more sensitive than the 
A673 to JQ1(+) treatment and corroborate the recently 
published ones from Hensel et al., performed in the 
same cell lines [45]. In addition, we have also shown 
that the BET bromodomains inhibition not only induces 
a dose-dependent inhibition, but also a time-dependent 
inhibition of EWS-Fli1 expression. Interestingly, a quick 
transcriptional inhibition of EWS-Fli1 expression after 
only one hour of 4 µM JQ1(+) treatment in the A673 and 
5 hours in TC71 cells compared to the DMSO treated-cells 
is observed (Figure 3C). The time-dependent EWS-Fli1 
expression impairment is also confirmed at a protein level, 
for both cell lines (Figure 3D). The rapid transcriptional 
effect of the BET inhibitor on EWS-Fli1 gene expression 
suggests the possibility that BET proteins may exert direct 
activation of the EWSR1 locus. To determine whether BET 
proteins bind directly to the EWS-Fli1 locus, we performed 
chromatin immunoprecipitation (ChIP) studies by using 
an antibody targeting BRD4 in A673 cells. We detected 
specific enrichment of BRD4 within the EWSR1 promoter 
region at several locations including both upstream and 
downstream sites relative to the transcriptional start site of 
the EWSR1 gene (Figure 3E). Furthermore, treatment of 
these cells with JQ1(+) induces the release of BRD4 from 
the promoter-binding sites. The increased enrichment for 
histone 3 lysine 27 acetylation (H3K27Ac) at the EWSR1 
promoter region indicates active transcription, perhaps 
Figure 1: Ewing Sarcoma cell lines overexpress BRD2, BRD3, BRD4 and EWS-Fli1 at mRNAs level and are sensitive 
to BET proteins inhibition. (A) Expression of BRD2, BRD3, BRD4 and (B) EWS-Fli1 at mRNA levels was evaluated by qRT–PCR 
in human Ewing Sarcoma cell lines compared with human mesenchymal stem cells (MSCs). GAPDH and B2M are used as housekeeping 
genes. Error bars show standard deviation for n = 3 measurements from representative experiments. (C) Chemical structure of the two JQ1 
enantiomers. (D) Human Ewing Sarcoma cell lines (A673, A673-1c, ASP14, EW7, EW24, IOR/BRZ, RDES, SKES-1, SK-N-MC, TC32 
and TC71) were cultured for 48 hours in the presence of JQ1(+) at the indicated concentrations and cell growth was determined by WST-1 
assay and compared with control (left panel). GI50 for JQ1(+) in tumor cell lines (right panel). These experiments were repeated at least 
twice. Error bars show standard deviation for n = 3 measurements from representative experiments.
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Figure 2: JQ1 inhibits the clonogenicity, the migratory potential and induces both a G1-phase cell cycle arrest and 
the apoptosis of human Ewing Sarcoma cell lines. (A) The TC71 Ewing Sarcoma cell line was plated at clonal density for colony 
numeration and treated with 4 µM JQ1(+) for 48 hours. Colony number was counted thanks to crystal violet staining performed after a 
6-days incubation time and pictures of representative wells were taken. These experiments were repeated at least twice. Error bars shows 
standard deviation for n = 3 measurements from representative experiments. A two-tailed paired Student’s t-test was used to compare the 
different conditions in the clonogenic assays. (B) The TC71 cells were cultured or not in presence of 4 µM JQ1(+) during 24 hours and 
were then plated in Boyden Chambers, always in presence of JQ1(+) for additional 48 hours. Error bars show the standard deviation for 
n = 8 measurements from representative experiments and a two-tailed paired Student’s t-test was used to compare the different conditions. 
(C) The TC71 Ewing Sarcoma cell line was treated with 1 µM JQ1(+) for 48 hours and the proportion of cells in G1, S, and G2 phase was 
determined by propidium iodide staining. (D) The TC71 Ewing Sarcoma cell line was treated with 4 µM JQ1(+) for 3, 6, 24 or 30 hours 
and the cell cycle-related proteins Rb, phosphorylated-Rb, CCNE1and CCND1 expression levels were evaluated by Western blotting (left 
panel). The expression of the same proteins was assessed after treating or not the cells with JQ1(+) at 0.4, 4 or 8 µM during twenty-four 
hours (right panel). (E) TC71 cells were treated with 4 µM of JQ1(+) or JQ1(–) for 3, 6, 24, 30 or 48 hours, and the apoptosis was evaluated 
by dosage of the caspase 3/7 activities. (F) The TC71 cell line was treated with 4 μM JQ1(+) for 6, 16, 24 or 48 hours and apoptosis was 
evaluated by cleaved poly (ADP-ribose) polymerase (PARP) level by Western blotting. (G) The apoptosis was evaluated by dosage of the 
caspase 3/7 activity in the TC71 Ewing Sarcoma cell line after JQ1(+) or JQ1(–) treatment at 1 or 10 µM during 24 hours. (H) The same cell 
line was treated with 0.4, 4 or 8 µM JQ1(+) or JQ1(–) for 24 hours and apoptosis was evaluated by cleaved poly (ADP-ribose) polymerase 
(PARP) level by Western blotting. For all the Western blotting experiments, the Glyceraldehyde-3-phosphate dehydrogenase was used as a 
loading control. These experiments were repeated at least twice. For the caspase 3/7 activity assays, error bars shows standard deviation for 
n = 3 measurements from representative experiments. A two-tailed paired Student’s t-test was used to compare the different conditions in 
these assays. For all the apoptosis assessment assays, a 6 hours Staurosporine (STS) treatment at 1 µM is used as a positive control.
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associated with super-enhancer region as recently described 
[41, 47]. Thus, these findings demonstrate that BRD4 is 
present on the EWSR1 promoter region and that JQ1(+) is 
able to deplete BRD4 from the promoter, thus inhibiting 
EWS-Fli1 transcription in Ewing Sarcoma cell lines.
In order to demonstrate that EWS-Fli1 is the key 
mediator of the JQ1(+) functional effects observed 
in Ewing Sarcoma cells, we performed experiments 
using the doxycycline-inducible shEWS-Fli1 ASP14 
cell line. We first confirmed the clonogenic-promoting 
effect of EWS-Fli1 in our model, highlighting the fact 
that suppressing EWS-Fli1 expression mimics the BET 
bromodomains inhibition effects on the Ewing Sarcoma 
cells clonogenic capabilities (Figure 3F, 3G). In order to 
check the crucial implication of EWS-Fli1 in the JQ1(+) 
response, we then assessed the cellular viability of the 
same cells after a JQ1(+) treatment, expressing or not 
EWS-Fli1 (Figure 3H). Our results show that under-
expressing EWS-Fli1 significantly reduces the sensitivity 
to a forty-eight hours JQ1(+) treatment at 6.5 µM. Taken 
together, those data emphasise and support the BET 
bromodomains implication in the EWS-Fli1 expression 
activation and supports the fact that JQ1 has an EWS-
Fli1-dependent activity in our model.
Inhibition of the BET proteins modulates the 
expression of EWS-Fli1 transcriptional-targets 
in a dose- and time-dependent manner
To confirm the downstream functional impact of the 
EWS-Fli1 transcriptional inhibition mediated by JQ1(+), 
the expression of some majors EWS-Fli1 target genes 
was evaluated. Thus it is now well established that Gli1 
[13, 48], NR0B1 [18] and p21 [22] are bona-fide direct-
EWS-Fli1 transcriptional targets, whereas the expression 
of both FOXM1 [19] and VEGFA [15] is reported to be 
indirectly under EWS-Fli1ʹs control, as no direct EWS-Fli1 
binding at their promoters was currently brought to light. In 
agreement with what we observed for EWS-Fli1 expression 
(Figure 3A), a twenty-four hours treatment with JQ1(+) 
inhibits Gli1 and NR0B1 mRNA expression in the two cell 
lines tested (Figure 4A and Supplementary Figure S4A). 
Furthermore, p21, whose expression is normally inhibited by 
EWS-Fli1, is increased by about 2-fold in these conditions 
(Figure 4A and Supplementary Figure S4A). In addition, 
the expression of two of the EWS-Fli1ʹs indirect target-
genes FOXM1 and VEGFA was also reduced consequently 
to a JQ1(+) treatment (Figure 4B and Supplementary 
Figure S4B). The same dose-dependent modulation of 
the EWS-Fli1-targets was confirmed at the protein level 
(Figure 4C and Supplementary Figure S4C). Furthermore, 
a time-course treatment with 4 µM JQ1(+) during 1, 2, 
5, 9 or 24 hours also highlighted a time-dependent 
modulation of Gli1, NR0B1, FOXM1 and CCND1 
(Figure 4D, 4E and Supplementary Figure S4D, 4E), 
which is however faster and more pronounced for the EWS-
Fli1 direct-targets than the indirect-ones. We observed 
the same tendency in the JQ1(+)-ability to modulate the 
aforementioned genes in a time-dependent manner at 
protein level (Figure 4F and Supplementary Figure S4F).
In order to confirm the EWS-Fli1-dependent 
modulation of the expression of Gli1, p21, NR0B1, FOXM1 
and VEGFA, we assessed the expression of all these genes 
in the ASP14 cell line, which bears a doxycycline-inducible 
shEWS-Fli1. EWS-Fli1 knock-down in these cells results 
in the inhibition of Gli1, NR0B1, FOXM1, VEGFA and 
CCND1 expression as well as the induction of p21 one 
(Supplementary Figure S4, S4I, S4J, S4K).
The BET proteins inhibition’s effects on EWS-
Fli1ʹs regulated pathways were also assessed. The MAPK/
ERK signaling has recently been suggested as a pivotal 
pathway in Ewing tumor proliferation and malignant 
progression [49]. Particularly, it was previously reported 
that the ERK1/2 proteins are constitutively activated in 
NIH3T3 cells transformed by an artificial expression of 
EWS-Fli1 [50]. We first confirmed this observation in our 
model. Indeed, an EWS-Fli1 knockdown in the ASP14 
cells consequently reduces the ERK1/2 phosphorylation-
marks, witnesses of the MAPK/ERK pathway activation 
(Supplementary Figure S4L). In accordance with these 
results, a dose- as well as a time-dependent inhibition of 
the ERK1/2 signaling was observed in both the TC71 and 
the A673 cell lines consequently to a JQ1(+) treatment 
(Figure 4G, 4H and Supplementary Figure S4G, S4H).
To support the EWS-Fli1-related cell cycle-
regulation of the Ewing Sarcoma cells, the Rb 
phosphorylation level as well as the CCNE1 and CCND1 
expression were evaluated in the shEWS-Fli1 inducible 
ASP14 model (Supplementary Figure S4M). A reduction 
in the Rb phosphorylation level and an inhibition of the 
CCNE1 and the CCND1 expression were observed, 
mimicking the BET bromodomain inhibition’s effects 
mediated by JQ1(+) on the cell cycle (Figure 2C, 2D and 
Supplementary Figure S2C, S2D). The gene expression 
signature and the modulation of the EWS-Fli1ʹs related-
pathways finally observed after EWS-Fli1 knock-down are 
in full agreement with the ones resulting from the BET 
bromodomain inhibition, reinforcing the assertion that 
JQ1(+) directly inhibits the Ewing Sarcoma malignant 
features through EWS-Fli1 signaling.
JQ1 delays Ewing Sarcoma growth and prolongs 
cancer-specific overall survival
To investigate the in vivo therapeutic potential of 
BET inhibition in Ewing Sarcoma, we used a human 
xenograft model known to recapitulate the features of 
the human pathology. 1.5 million TC71 tumor cells 
were implanted in paratibial in athymic mice, and mice 
were then intraperitoneally (IP) injected with JQ1(+) 
(50 mg/kg) or vehicle twice a day when the tumor 
volume reaches 100 mm3 (Figure 5A). JQ1(+) treatment 
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significantly reduced the average tumor growth in our 
model (Figure 5B). Moreover, the Kaplan-Meier analysis 
revealed that BET proteins inhibition significantly 
prolonged the overall survival of tumor-bearing mice 
(Figure 5C). Expression analysis for EWS-Fli1 was 
performed by qRT-PCR on the mice tumor biopsies. 
Figure 3: JQ1(+) treatment in Ewing Sarcoma cells induces a dose- and a time-dependent EWS-Fli1 down-regulation. 
(A) qRT–PCR for EWS-Fli1 RNA levels in DMSO or JQ1(+)-treated A673 and TC71 Ewing Sarcoma cell lines at different doses for 
24 h. GAPDH and B2M expression are used as housekeeping genes. Error bars show standard deviation for n = 3 measurements from 
representative experiments. (B) The A673 (left panel) and TC71 (right panel) Ewing Sarcoma cell lines were treated with 0.4, 4 or 8 µM 
JQ1(+) for 24 hours and the EWS-Fli1 expression level was evaluated by Western blotting. Glyceraldehyde-3-phosphate dehydrogenase 
was used as a loading control. (C) qRT–PCR for EWS-Fli1 RNA levels in DMSO, JQ1(+)-treated A673 (left panel) and TC71 (right panel) 
Ewing Sarcoma cell lines at different time points, from one to nine hours (4 µM JQ1(+)). GAPDH and B2M are used as housekeeping 
genes. Error bars show standard deviation for n = 3 measurements from representative experiments. (D) Immunoblotting of the EWS-Fli1 
expression in the same cell lines as represented in (C) treated by JQ1(+) for 6, 16, 24 or 48 hours at 1 µM. Actin was used as a loading 
control. (E) ChIP with a BRD4 antibody at three sites within the EWS-Fli1promoter region in A673 cells treated with 4 µM JQ1(+) for 
5 h 30. Enrichment is shown as the percentage of total input DNA. Error bars show standard deviation for n = 3 measurements from 
representative experiments. The top track show the levels of enrichment of the H3K27Ac histone mark across the genome as determined 
by a ChIP-seq assay on seven cell lines from ENCODE. (F) The EWS-Fli1 expression was assessed at mRNA level in the ASP14 cell line 
treated or not with 1 µg/mL Doxycycline for 48 or 72 hours, to induce the shEWS-Fli1 transcription. The EWSFli1expression was assessed 
at mRNA level after qRT-PCR (upper panel) and at protein level after Immunoblotting (lower panel). GAPDH and B2M are used as 
housekeeping genes in the qRT-PCR assays. Error bars show standard deviation for n = 3 measurements from representative experiments. 
Glyceraldehyde-3-phosphate dehydrogenase was used as a loading control for the Western blotting. (G) ASP14 Ewing Sarcoma cells 
were treated or not with 1 µg/mL Doxycycline during 72 hours to induce the shEWS-Fli1 transcription and plated at clonal density for 
colony counts thanks to crystal violet staining performed after a 6-days incubation time. For all the clonogenic assays, error bars show the 
standard deviation for n = 6 measurements from representative experiments and a two-tailed paired Student’s t-test was used to compare 
the different conditions. (H) ASP14 Ewing Sarcoma cells were treated or not with 1 µg/mL Doxycycline during 72 hours to induce the 
shEWS-Fli1 transcription and 2000 cells per well were seeded in 96-wells plates. The cells were then treated with 6.5 µM JQ1(+) or 
the same amount of DMSO. The cell viability was assessed after 48 hours by WST-1 assay. Error bars show the standard deviation for 
n = 3 measurements from representative experiments and a two-tailed paired Student’s t-test was used to compare the different conditions.
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Figure 4: JQ1(+) treatment in Ewing Sarcoma cells induces a dose- and a time-dependent modulation of pathways 
under the control of EWS-Fli1. (A) qRT–PCR for EWS-Fli1 direct-target genes (Gli1, NR0B1 and p21) and (B) EWS-Fli1indirect-
target genes (FOXM1 and VEGFA) in DMSO or JQ1(+)-treated Ewing Sarcoma A673 cell line during 24 h, at 1 and 10μM JQ1(+). 
(C) FOXM1-, NR0B1- and p21-EWS-Fli1-target gene expression was evaluated at protein level by Immunoblotting in the A673 Ewing 
Sarcoma cell line after JQ1(+) treatment at 0.4, 4 or 8 µM during 24 h. Glyceraldehyde-3-phosphate dehydrogenase was used as a loading 
control. (D) qRT–PCR for EWS-Fli1 direct target genes (Gli1and NR0B1) and (E) EWS-Fli1 indirect-target genes (FOXM1 and CCND1) 
in DMSO (Veh.) or JQ1- (+)-treated Ewing Sarcoma A673 cells at 4 µM during 1, 2, 5, 9 and 24 hours. (F) FOXM1-, NR0B1- and p21-
EWS-Fli1-target gene expression was evaluated at protein level by Immunoblotting in the A673 Ewing Sarcoma cell line after JQ1(+) 
treatment or not during 3, 6, 24, or 30 hours. (G) ERK ½ phosphorylation level was evaluated by Immunoblotting in the A673 Ewing 
Sarcoma cell line after a 24 hours JQ1(+) treatment at 0.4, 4 or 8 µM or after a 4 µM JQ1(+) treatment during 3, 6, 24, or 30 hours (H). All 
the Western blots were performed at least twice and representative blots are presented. Glyceraldehyde-3-phosphate dehydrogenase was 
used as a loading control. For all the qRT-PCR, GAPDH and B2M are used as housekeeping genes and error bars show standard deviation 
for n = 3 measurements from representative experiments.
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Accordingly to our in vitro results, we observed a 
significant repression of EWS-Fli1 expression in the 
mice cohort treated with JQ1(+) (Figure 5D). In order to 
functionally validate the JQ1(+)-mediated transcriptional 
repression of EWS-Fli1 in our in vivo model, we also 
examined the EWS-Fli1 direct- and indirect-target genes 
Gli1, p21, FOXM1, VEGFA and CCND1 expression 
(Figure 5D). As expected, Gli1, FOXM1, VEGFA and 
CCND1 expression were significantly decreased in 
the JQ1(+) treated group, whereas the one of p21 was 
increased. However no statistical change was observed 
concerning the NR0B1 expression in these conditions 
(Supplementary Figure S5A).
To better characterize the functional effect of the 
BET bromodomains inhibition within the tumoral-tissue, 
immunohistochemical staining for the proliferative marker 
Ki67 was performed. Tumor biopsies from JQ1(+)-treated 
mice display a statistically significant decreased cell 
proliferation compared with their untreated counterparts 
(Figure 5E). In addition, a correlation between the 
Ki67 staining and EWS-Fli1 expression is observed 
in the tumor samples, (Supplementary Figure S5B). 
Immunohistochemical staining for the caspase-3 activity 
was also assessed in these samples and the results 
show an higher induction of apoptosis in the JQ1(+) 
cohort (Figure 5F). Because of the in vitro decrease of 
the VEGFA expression observed after inhibition of 
BET proteins, we determined the JQ1(+) effect on the 
vascularization within the tumors by performing a CD146 
immunohistochemical staining. Different vascularization-
parameters were estimated, and JQ1(+) not only inhibits 
the global vascularization, but also contributes to reduce 
the average vessels size (Figure 5G). Collectively, these 
in vivo data suggest that the potent anti-tumor activity 
of JQ1(+) in Ewing Sarcoma is mediated through its 
inhibitory effects on the EWS-Fli1oncogene expression 
and its transcriptional targets.
DISCUSSION
Since EWS-Fli1 was identified as the crucial driver-
oncogene in Ewing Sarcomas, it is considered as the best 
therapeutic target for this pathology. Impairing its activity 
through a direct inhibition of its transcript is indeed a 
seducing strategy to reduce the malignant features of the 
Ewing Sarcoma cells. In this perspective, mithramycin, 
trabectedin and the so-called YK-4–279, an inhibitor of 
the EWS-Fli1/RNA helicase A interaction have recently 
been uncovered as potent EWS-Fli1 transcription factor 
activity inhibitors [51–53], however without inhibiting the 
transcription of this oncogene itself. Consequently, novel 
strategies implicating an early control of its expression, 
upstream its transcription could be of great interest in this 
context.
In this study, we highlight the essential implication 
of BET bromodomain signaling in the control of EWS-
Fli1 expression, as well as the potential application of BET 
bromodomain inhibitors as powerful antitumor agents in 
Ewing Sarcoma.
The recently identified “super-enhancers” regions 
are large DNA portions, characterized by both a high 
density of cell type-specific master transcription factors 
and a H3K27Ac enrichment [54]. Such enhancers fine-
tune the expression of key cell-identity genes and are 
consequently implicated in the cell fate determination 
since they allow adaptations of the transcriptional program 
to the cell environment. Considering both the central role 
of EWS-Fli1 in Ewing Sarcoma and the cell’s addiction 
to this oncogene, we hypothesized that super enhancers 
might govern its expression.
We herein demonstrated that treating Ewing 
Sarcoma cells with JQ1, a BET bromodomain inhibitor 
reduces their viability, their clonogenic features as well 
as their migratory capabilities. Moreover, it also leads to 
a G1-phase arrest, characterized by a P-Rb, a CCND1 
and a CCNE1 reduced expression. This cell-cycle effect 
was reproduced in a shEWS-Fli1 induced model and is 
in agreement with previously published data reporting the 
same results down-regulating EWS-Fli1 with antisense 
oligonucleotides [12]. In addition, we have shown that 
this disturbance of the cell-cycle ultimately leads to an 
apoptotic cell-death, mediated by the caspase 3/7 pathway 
and resulting in the PARP cleavage.
The functional effects of the BET bromodomain 
inhibition observed in our Ewing Sarcoma models are 
indeed attributable to the strong reduction in the oncogenic-
driver EWS-Fli1 expression, which are both dose- and 
time-dependent. We indeed demonstrated for the first 
time through chromatin immunoprecipitation that BRD4 
actively binds to the EWS-Fli1 promoter, at H3K27Ac 
enriched sites. As a consequence, we also showed that a 
JQ1(+) treatment leads to the release of BRD4 from the 
EWS-Fli1 promoter. Interestingly, it was recently reported 
that the H3K27Ac were the histone marks the most 
strongly inhibited by EWS-Fli1 knockdown [43]. This 
information sheds light on the possibility that the reduced 
EWS-Fli1 expression mediated by BET bromodomain 
inhibitors such as JQ1(+) could also lead to a generalized 
transcriptional inhibition, as well as having a consequent 
downstream effect on the EWS-Fli1 controlled-target 
genes. Our work demonstrated that it reduces in a 
dose- and in a time-dependent manner the expression of 
Gli1, NR0B1, FOXM1 and VEGFA, some of the EWS-
Fli1 target-genes considered as determining factors 
in the carcinogenesis of Ewing Sarcoma [19, 55–57]. 
In addition, we have also demonstrated that the JQ1(+)-
mediated BET bromodomain inhibition has a consequent 
downstream effect on the ERK1/2 signaling, one of the 
pathways that EWS-Fli1 normally activates and which 
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contributes to the preservation of the Ewing Sarcoma 
malignant features [49].
The antitumor effects of JQ1(+) on Ewing 
Sarcoma were also confirmed in vivo, as intra-peritoneal 
administrations of JQ1(+) significantly improve the overall 
survival of tumor-bearing nude mice through delaying the 
tumor growth. Our histological analyses point that the cells 
within the tumors of the treated-animals display a slowed 
proliferation and are more prone to apoptotic death. 
The results of our in vivo orthotopic model are in full 
agreement with those of Hensel et al. in their subcutaneous 
heterotopic Ewing Sarcoma model [45]. In addition, the 
BET inhibitory treatment leads to a significant reduction 
of both the global tumor-vascularization as well as the 
VEGFA expression within the tumor-cells. These results 
corroborate the decreased expression of this angiogenesis 
regulator, which is also one of the EWS-Fli1 target genes, 
observed in vitro. Interestingly, VEGF was reported to 
Figure 5: JQ1(+) significantly delays tumor growth in TC71 xenograft model and prolongs cancer-specific survival. (A) 
Experimental design: 1.5 million TC71 Ewing Sarcoma cells were injected paratibially in nude mice. Mice were IP injected with 50 mg/kg 
JQ1(+) or vehicle (10% HP-β-CD) twice a day for the indicated time when tumor volume reached 100 mm3. (B) The mean tumor volume 
of mice treated was compared with control group ± s.e.m (n = 8 mice in each group).Two-way ANOVA statistical test was used. (C) In 
Kaplan–Meier curves, cancer-specific survival were compared between mice treated with JQ1(+) and control. The log-rank (Mantel- Cox) 
test was used to compare the overall survival between groups. (D) EWS-Fli1, Gli1, p21, FOXM1, VEGFA and CCND1 expressions were 
evaluated in tumor tissues, after RNA extraction, by qRT–PCR. For all the qRT-PCR, GAPDH and B2M are used as housekeeping genes. 
Unpaired two-tailed t-test was used to compare the gene expression between groups. (E) Tumors were collected at the time of euthanasia 
and Ki67 was evaluated by immunohistochemical analysis (original magnification, 200; scale bar, 100 µm). (F) Tumors were collected 
at the time of euthanasia and caspase 3 activity was evaluated by immunohistochemical analysis (original magnification, 50; scale bar, 
250 µm). (G) Tumors were collected at the time of euthanasia and CD146 staining was performed by immunohistochemical analysis (left 
panel). The size of vessels (right panel) was also calculated thanks to the Image J software. For each mouse, ten pictures were taken and 
were scored and estimated in % of positive cells ± s.d. for DAB activity, in the delimited region of interest (ROI) within the tumor. Error 
bars show s.d. for n = 80 pictures. 
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play an important prognostic role in soft tissue sarcomas 
and in Ewing tumors, as its expression correlates with a 
poor patient survival [15, 58].
In conclusion, our results shed light on the BET 
bromodomains’ role, especially BRD4ʹs one, as essential 
regulators of Ewing Sarcoma carcinogenesis. Indeed, 
we herein bring novel glimpse at their requirement in 
the control of EWS-Fli1ʹs expression, the master Ewing 
Sarcoma-specific oncogene. BET bromodomain protein 
inhibition consequently impacts EWS-Fli1ʹs downstream 
signaling, which is functionally decisive for the 
interference in the tumorigenic program of these cancer-
cells. The work presented in this study provides support 
for evaluating the BET bromodomain-related protein 
family as a promising therapeutic target. 
MATERIALS AND METHODS
Tumor cell lines
Ten human Ewing Sarcoma cell lines were used: 
the A673 (young 15 years old female Ewing Sarcoma 
from muscle origin), TC32 (young 31 month female from 
solid primitive neuroectodermal origin), SKES-1 (young 
18 years old Caucasian male Ewing Sarcoma from bone 
origin), SK-N-MC (young 14 years old Caucasian female 
from neurogenic origin) and RDES (young 19 years old 
Caucasian male Ewing Sarcoma from bone origin) cell 
lines were kindly provided by Dr. S. Burchill (Children’s 
Hospital, Leeds, United Kingdom) and the EW24 and 
TC71 cell lines by Dr. O. Delattre (Institut National de la 
Santé et de la Recherche Médicale U830, Paris, France). 
The A673-1c and the ASP14 (A673/TR/shEF) cells 
were kind gifts from Dr. F. Tirode (Institut Curie, Paris, 
France) and F. R. Alonso Garcia de la Rosa (Instituto de 
Investigacion en Enfermedades Raras, Instituto de Salud 
Carlos III, Majadahonda, Spain) respectively. The ASP14 
cells were cultured in presence of zeocin 50 µg/mL and 
blasticidin 2 µg/mL, and the shEWS-Fli1 system was 
induced by adding 1 µg/mL doxycycline. The cell lines 
A673, A673-1c, ASP14, TC32, SKES-1 and RDES were 
cultured in Dulbecco’s modified Eagle’s medium (DMEM; 
Invitrogen-Life Technologies Inc.) supplemented with 
10% fetal bovine serum (FBS; Hyclone) and 2 mmol/L 
L-glutamine. The SK-N-MC, STAET-1, EW7, EW24, 
and TC71 cells were cultured in RPMI (Invitrogen-Life 
Technologies Inc.) with 10% FBS. The IOR/BRZ cells 
were cultured in Iscove’s modified Dulbecco’s medium 
(IMDM Invitrogen-Life Technologies Inc.) with 10% FBS 
and 2 mmol/L L-glutamine. All cell lines were cultured 
in the presence of 1% penicillin/streptomycin and type 
I collagen (Sigma-Aldrich) was required to allow the 
STAET-1, TC71and EW7 cells to grow. All cell lines were 
cultured in a humidified 5% CO2/air atmosphere at 37°C 
and were passaged for less than 3 months.
Therapeutic agents
BRD4 inhibitor, JQ1, was kindly provided by 
James Bradner (Dana-Farber Cancer Institute). This 
synthetic compound targets selectively the acetyl-lysine-
binding pocket of the BET bromodomain proteins. For 
in vitro studies, JQ1 was dissolved in dimethyl sulphoxide 
(DMSO) at 10mM stock solutions and stored at –20°C. 
For the in vivo studies, JQ1 was dissolved in DMSO at 
50 mg/ml and then diluted in 10% hydroxypropyl beta 
cyclodextrin (HP-β-CD, Sigma-Aldrich) to get the final 
dose, 50 mg/kg and stored at 4°C. The 10% HP-β-CD is 
prepared in sterile water, which was filtered with 0.22 µm 
filter. During this study, the active enantiomer of JQ1 was 
called JQ1(+), whereas the inactive one was called JQ1(–).
Cell proliferation assay and GI50 calculation
Ewing Sarcoma cell lines were plated in 96-wells 
plates in the appropriate medium with 10% FBS and 
treated with JQ1 at indicated concentration and time and 
cell growth was measured using the WST-1 assay (Roche, 
Mannheim, Germany). At the end of the incubation time, 
culture medium is removed and replaced by the WST-1 
reagent diluted in fresh medium in a 1:10 proportion. 
After a 7 hours incubation time, the absorbance at 470 nm 
of each well was measured on a 96-multiwellmicroplate 
reader (Victor² 1420; PerkinElmer Inc.) and normalized 
to the average reading of wells containing medium only. 
Each assay was performed in triplicate. The GI50 were 
calculated thanks to the GraphPad Prism 6 software.
Quantitative reverse transcription–PCR
Total RNA was extracted from cultured cells or from 
crushed-xenograft samples using QIAzol Lysis Reagent 
(QIAGEN) and the miRNeasy Mini Kit (QIAGEN) 
according to the manufacturer’s instructions. Total RNA 
was reversed transcribed using the Thermo Script RT-
PCR System (Life Technologies). Real-time monitoring 
of PCR amplification of complementary DNA was 
performed using DNA primers on CFX96 real-time PCR 
detector system (Bio-Rad, Marnes la Coquette, France) 
with SYBR PCR Master Mix buffer (Bio-Rad). Target 
gene expression was normalized to glyceraldehyde 
3-phosphate dehydrogenase and β-2 microglobulin 
levels in respective samples as an internal standard, and 
the comparative cycle threshold (Ct) method was used 
to calculate relative quantification of target messenger 
RNAs. Each assay was performed in triplicate. The 
primers sequences are the following: B2M FW: 
5ʹ-TTCTGGCCTGGAGGCTATC-3ʹ, RV: 5ʹ-TCAGGAA 
ATTTGA-3ʹ; BRD2 FW: 5ʹ-GCTTTAGGCCCTTCTG 
GCTT-3ʹ, RV: 5ʹ-ATCATAACCTGTAGGCAGGGC-3ʹ; 
BRD3 FW: 5ʹ- CTGAAACCCACCACTTTGCG-3ʹ, RV: 
5ʹ- GCTCCTCTTTCGACTTGGCT-3ʹ; BRD4 FW: 5ʹ- G 
CTCAGGAATGTATCCAGGACT-3ʹ, RV: 5ʹ- CCAGAG 
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CTTCTGCCATTAAGA-3ʹ; BRDT FW: 5ʹ-TGACATCT 
CTCTCTCGCCCT-3ʹ, RV: 5ʹ-CTCGCCTCTTCACACC 
CTTT-3ʹ; CCND1 FW: 5ʹ-GCCGAGAAGCTGTGCA 
TC-3ʹ, RV: 5ʹ-CCACTTGAGCTTGTTCACCA-3ʹ; EWS-
Fli1 FW: 5ʹ-GCCAAGCTCCAAGTCAATATAGC-3ʹ, 
RV: 5ʹ- GGGCCGATTCATGTTATTGC-3ʹ; FOXM1 FW: 
5ʹ-GCAGGCTGCACTATCAACAA-3ʹ, RV: 5ʹ-TCGAAG 
GCTCCTCAACCTTA-3ʹ; GAPDH FW: 5ʹ-TGGGTGTG 
AACCATGAGAAGTATG-3ʹ, RV: 5ʹ-GGTGCAGGAGG 
CATTGCT-3ʹ; Gli1 FW: 5ʹ-ACCCGGGGTCTCAAAC 
TG-3ʹ, RV: 5ʹ-GGCTGACAGTATAGGCAGAGC-3ʹ; NR 
0B1 FW: 5ʹ-TGCTCTTTAACCCGGACGTG-3ʹ, RV: 
5ʹ-GCGTCATCCTGGTGTGTTCA-3ʹ; p21 FW: 5ʹ-CGA 
AGTCAGTTCCTTGTGGAG-3ʹ, RV: 5ʹ-CATGGGTTC 
TGACGGACAT-3ʹ;VEGFA FW: 5ʹ-CCTTGCTGCTCTA 
CCTCCAC-3ʹ, RV: 5ʹ-CCACTTCGTGATGATTCTGC-3ʹ.
2D Clonogenic assay
Ewing Sarcoma cells were seeded at a density of 
1000 cells per well in 6-well plate and treated with 4 µM 
of JQ1(+), JQ1(–) or the corresponding amount of DMSO 
for 48 hours. Culture medium was then replaced by fresh 
one and the cells were cultured for additional 6 days. The 
colonies were then washed in PBS, fixed for 10 min with 
glutaraldehyde 10% and stained with crystal violet (1% 
in water) for 10 min at room temperature. Pictures of the 
stained wells were taken and the stained surfaces/ total 
areas of each well were calculated thanks to the ImageJ 
software. Each assay was performed in triplicate and two 
areas per well were randomly chosen to take pictures.
Boyden chamber assay
Ewing Sarcoma cells were cultured or not in 
presence of JQ1(+) during 24 hours and 20 000 cells were 
then plated in 8 µm-pored Boyden Chambers (Falcon), 
always in presence of JQ1(+), in 1% FBS growth medium 
for additional 48 hours. A 1%/10% FBS-gradient was 
generated between the upper and the lower Chamber of 
the system, to promote the cell migration. At the end of the 
incubation time, the cells on the upper side of the Chamber 
were mechanically removed and those on the lower side 
of the Chamber were fixed with 10% Glutaraldehyde and 
stained with 0.1% Crystal Violet. Pictures of the Chambers 
were taken and four different areas were arbitrary chosen 
to perform quantitative analyses. The ratio « colored 
surface/ total surface » was determined thanks to the 
ImageJ software. Representative pictures of the Boyden 
were chosen here. For all the Boyden Chambers 
experiments, error bars show the standard deviation for 
n = 8 measurements from representative experiments and 
a two-tailed paired Student’s t-test was used to compare 
the different conditions.
Cell cycle analysis
Ewing Sarcoma cell lines were incubated in the 
presence of 1 µM JQ1 for 48 h, trypsinized, washed and 
fixed in 70% ethanol for 30 minutes at 4°C. The cells are 
then washed, centrifugated and the pellet is resuspended 
in a phospho-citrate solution (Na2HPO4 0.2 M; citric acid 
0.1 M, pH 7.5). Cells were centrifugated and resuspended 
in a PBS solution containing 4 mg/ml Ribonuclease 
A for 30 min at 37°C. 50 mg/ml propidium iodide was 
then added to each sample for 20 min at 4°C and the cell 
cycle distribution was then analysed by flow cytometry 
(Cytomics FC500; Beckman Coulter, Roissy, France) 
based on 2 N and 4 N DNA content. Multi Cycle AV DNA 
Analysis software was used to process the data.
Western blotting analysis
Samples containing equal amounts of protein 
(depending on the antibody, 15–75 mg) from lysates 
of cultured Ewing Sarcoma cell lines underwent 
electrophoresis on SDS-PAGE and were transferred 
to polyvinylidenedifluoride (PVDF) membranes. The 
membranes were blocked in 3% BSA-PBS-0.05% Tween 
at room temperature for 1 h and blots were probed 
overnight at 4°C with the following primary antibodies: 
rabbit anti-Fli1 c-19 sc-356, 1:500; rabbit anti-p21 (c-19) 
sc-397#DO312, 1:200; rabbit anti-FOXM1 c20 sc-502, 
1:100; Santa Cruz Biotechnologies, Santa Cruz, CA; 
rabbit anti-NR0B1 (DAX1) #13538, 1:1000; rabbit 
anti-P-44/42 MAPK (T202/Y204) #4370S, 1:2000; 
rabbit anti-p44/42 #9102S, 1:1000; mouse anti-Rb, 4H1 
#9309S, 1:1000; rabbit anti-P-Rb (ser807–811) #9308S, 
1:1000; rabbit anti-CCND1#2922S 1:1000; mouse 
anti-CCNE1 (HE12) #4129S 1:1000; rabbit anti-PARP 
#9542S, 1:1000; rabbit anti-GAPDH 14c10, 1:2000; 
Cell Signaling Technologies, Beverly, CA; rabbit anti-
actinA5060 (20–33) 1:10 000; Sigma-Aldrich; to detect 
proteins of interests. After incubation, the membranes 
were washed three times with washing buffer (PBS 
containing 0.05% Tween) for 5 min. Membranes were then 
saturated 1 h with 5% milk-PBS-0.05% Tween (Régilait). 
Membranes were finally incubated for 1 h with secondary 
antibodies (goat-anti-rabbit sc-2004 #J1512, 1:10000; 
donkey-anti-mousesc-2314 #C2012 1:5000; Santa Cruz 
Biotechnologies, Santa Cruz, CA) at room temperature. 
Specific proteins were detected using SuperSignal® 
WestDura Extended Duration Substrate (ThermoScientific, 
Rockford, USA) and a G-Box (Syngene, Cambridge, 
UK) after washing. Pictures were analysed thanks to 
ImageJ software. Actin and Glyceraldehyde-3-phosphate 
dehydrogenase were used as an internal loading control. 
The relative quantization of EWS-Fli1 expression 
(Supplementary Figure S3) was performed thanks to 




Cellular viability was determined using the Trypan 
Blue dye exclusion method (Trypan Blue, Eurobio, les 
Ulis, France; final dye concentration: 0.1% w/v) and a 
hemocytometer. The caspase 3/7 activity was assessed 
thanks to the apo-ONE® Homogeneous caspase-3/7 
Assay kit (Promega, Madison, USA) according to the 
manufacturer’s instructions. Each assay was performed in 
triplicate.
Quantitative ChIP assay
A ChIP assay was performed by the Magnify ChIP 
system (Invitrogen-Life Technologies Inc.) using 5 mg of 
BRD4 antibody (BethylLab) or control rabbit IgG (R & D 
Systems). Real-time PCR (Bio-Rad) was performed on 
fragmented DNA using specific primers for the EWSR1 
loci. Primers were designed to amplify sites within 
each gene locus based on the H3K27 acetylation level. 
The levels of enrichment of the H3K27Ac histone mark 
across the genome has been determined by a ChIP-seq 
assay on seven cell lines from ENCODE web resources. 
We used the following primers: EWSR1–1 sense 5ʹ- 
CCGTAAACCTCCTCCTGCAT-3ʹ and anti-sense 5ʹ- 
AAGCCCTTCACCCTTGCTAA-3ʹ ; EWSR1–2 sense 
5ʹ- GCAGTTGTTCTAGTCCGGGT-3ʹ and anti-sense 
5ʹ- CCGCAACTCTTGTCCCAGTC-3ʹ ; EWSR1–3 
sense 5ʹ- AAGACTGAGTGGAGTTGCCG-3ʹ and anti-
sense 5ʹ- GAAGATTCCAGAACCGGCCC-3ʹ. For the 
ChIP-qPCR, error bars show standard deviation for 
n = 3 measurements from representative experiments. 
Each assay was performed in triplicate.
Animal treatment
All procedures involving mice (their housing in the 
Experimental Therapeutic Unit at the Faculty of Medicine 
of Nantes (France) and care, the method by which they 
were anaesthetized and killed, and all experimental 
protocols) were conducted in accordance with the 
institutional guidelines of the French Ethical Committee 
(CEEA.PdL.06). Mice were anaesthetized by inhalation 
of a combination of isoflurane/air (1.5%, 1 l/min) and 
buprenorphine (0.05 mg/kg; Temge´sic, Schering-
Plough). Tumor volume was measured three times weekly 
and tumor volume was calculated by using the formula: 
length*width*depth*0.5. Data points were expressed as 
average tumor-volume ± s.e.m. Xenograft models were 
induced by a paratibial injection of 1.5.106 TC71 cells of 
5-week-old female athymic nude mice (Harlan Sprague–
Dawley Inc.), leading to a rapidly growing tumor in soft 
tissue with secondary contiguous bone invasion. Once 
palpable tumors, mice were randomly assigned to vehicle 
or JQ1(+). When tumors reached 100 mm3, JQ1(+) 
(50 mg/kg; formulation in 10% HP-β-CD in sterile water) 
is IP injected twice a day, every day. Each experimental 
group consisted of eight mice. When tumor volume 
reached 10% of body weight, mice were killed and tumor 
biopsy samples were collected for evaluation of mRNA 
expression by RT-qPCR analyses. Tumors were also 
harvested for immunohistochemistry analyses.
Immunohistochemistry
Immunostaining for Ki67 was conducted using a 
primary antibody mouse anti-human Ki67 (M7249, 1:100; 
Dako) on tumor section. Immunostaining for CD146 was 
conducted using a primary antibody rabbit anti-human 
CD146 (ab75769, 1:800; Abcam) on tumor section. 
Immunostaining for Cleaved caspase-3 was conducted 
using a primary antibody rabbit anti-human Cleaved 
Caspase-3 (9664, 1:400; Cell Signaling) on tumor 
section. All analyses were assessed by light microscopy 
using a DMRXA microscope (Leica). The comparisons 
of Ki67 and CD146 staining intensities were made 
at ×200 magnifications whereas ones of Cleaved 
caspase-3 were made at ×50 magnifications. Pictures 
were taken thanks to the NDP.view 2 Hamamatsu 
software, and the quantization of the staining intensities 
was performed with ImageJ. For each histological-slide 
from the tumor-sample of one mouse, 10 areas were 
arbitrary chosen to represent the whole tumor section. The 
ImageJ ImmunoRatio version 1.0c 14.2.2011 plugin was 
used to carry out the Ki67 analysis on these 10 areas. All 
the histograms presented in the Figures result from the 
average of the DAB-positive surface counting performed 
on the 10 areas selected for the eight mice per group. 
The vessels size assessment is based on a pixel scale and 
according to the results table of the ImageJ software, it 
corresponds to the average vessel perimeter.
Statistical analysis
For each experimental data point, the standard 
deviation from replicate experiments was calculated 
as noted in the legends and is shown as error bars. All 
error bars show standard deviation for at least triplicate 
measurement from representative experiments. The 
mean ± s.d was calculated for all groups and compared 
by two-tailed paired Student’s t-test or by ANOVA 
analysis of variance. Error bars from the in vivo tumor 
growth monitoring represent the s.e.m from the mean 
tumor volume of the mice (n = 8 mice in each group). 
P < 0.05 was used as the criteria for statistical significance. 
For the Supplementary Figure S5B, the Pearson product-
moment correlation coefficient (R²) was calculated. 
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